Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + lenalidomide
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Belantamab mafodotin + lenalidomide is a combination therapy being investigated for the treatment of multiple myeloma. Belantamab mafodotin (Blenrep) is an antibody-drug conjugate (ADC) developed by GSK that targets B-cell maturation antigen (BCMA). It consists of a humanized anti-BCMA monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF) via a non-cleavable maleimidocaproyl linker. Lenalidomide (Revlimid) is an oral immunomodulatory imide drug (IMiD) that binds to cereblon, part of the E3 ubiquitin ligase complex, leading to the degradation of Ikaros and Aiolos transcription factors. This combination is specifically being evaluated by Roswell Park Cancer Institute in a Phase 2 trial as consolidation therapy for patients with multiple myeloma who remain minimal residual disease (MRD) positive after autologous stem cell transplantation (ASCT).
- Other names
- belamaf + lenalidomide
02
Targets
BCMA (B-cell maturation antigen)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on belantamab mafodotin + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + lenalidomide.